Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination
Cancer Letters · 2024-08 · 598 · 217079
DOI: 10.1016/j.canlet.2024.217079 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2024-08. Verfasst von Zhaokai Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Adoptive, Immunogenic Cell Death, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 383 Literaturangaben. Gefördert von: Zhengzhou University.
Abstract (Originalsprache)
Immunogenic cell death (ICD) is a stress-driven form of regulated cell death (RCD) in which dying tumor cells' specific signaling pathways are activated to release damage-associated molecular patterns (DAMPs), leading to the robust anti-tumor immune response as well as a reversal of the tumor immune microenvironment from "cold" to "hot". Chimeric antigen receptor (CAR)-T cell therapy, as a landmark in anti-tumor immunotherapy, plays a formidable role in hematologic malignancies but falls short in solid tumors. The Gordian knot of CAR-T cells for solid tumors includes but is not limited to, tumor antigen heterogeneity or absence, physical and immune barriers of tumors. The combination of ICD induction therapy and CAR-T cell immunotherapy is expected to promote the intensive use of CAR-T cell in solid tumors. In this review, we summarize the characteristics of ICD, stress-responsive mechanism, and the synergistic effect of various ICD-based therapies with CAR-T cells to effectively improve anti-tumor capacity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
- Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
- Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Henan Province Key Laboratory of Cardiac Injury and Repair, Henan Province Clinical Research Center for Cardiovascular Diseases, Zhengzhou…
- Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
- State Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, C…
Förderung
- Zhengzhou University
Zitieren
APA
Zhou, Z., Mai, Y., Zhang, G., Wang, Y., Sun, P., Jing, Z., Li, Z., Xu, Y., Han, B., & Liu, J. (2024). Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination. Cancer Letters, 598, 217079. https://doi.org/10.1016/j.canlet.2024.217079
Vancouver
Zhou Z, Mai Y, Zhang G, Wang Y, Sun P, Jing Z, et al. Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination. Cancer Letters. 2024;598:217079. doi:10.1016/j.canlet.2024.217079
BibTeX
@article{Zhou2024,
author = {Zhou, Zhaokai and Mai, Yumiao and Zhang, Ge and Wang, Yingjie and Sun, Pan and Jing, Zhaohe and Li, Zhengrui and Xu, Yudi and Han, Bo and Liu, Jian},
title = {Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination},
journal = {Cancer Letters},
year = {2024},
volume = {598},
pages = {217079},
doi = {10.1016/j.canlet.2024.217079}
}
EUVIMED